Skillman, New Jersey-based Kenvue Inc. (KVUE) operates as a global consumer health company. Valued at $41.9 billion by market cap, the company offers a consumer health portfolio in self-care, skin health & beauty, and essential health products. The world’s largest pure-play consumer health company is expected to announce its fiscal second-quarter earnings for 2025 on Tuesday, Aug. 5.
Ahead of the event, analysts expect KVUE to report a profit of $0.28 per share on a diluted basis, down 12.5% from $0.32 per share in the year-ago quarter. The company beat or matched the consensus estimate in each of the last four quarters.
For the full year, analysts expect KVUE to report EPS of $1.12, down 1.8% from $1.14 in fiscal 2024. However, its EPS is expected to rise 8.9% year over year to $1.22 in fiscal 2026.
KVUE stock has outperformed the S&P 500 Index’s ($SPX) 10.9% gains over the past 52 weeks, with shares up 18.1% during this period. Similarly, it outperformed the Consumer Staples Select Sector SPDR Fund’s (XLP) 4% gains over the same time frame.
On May 8, KVUE shares closed up more than 4% after reporting its Q1 results. Its adjusted EPS of $0.24 topped Wall Street expectations of $0.22. The company’s revenue was $3.74 billion, topping Wall Street forecasts of $3.68 billion.
Analysts’ consensus opinion on KVUE stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 15 analysts covering the stock, five advise a “Strong Buy” rating, and 10 give a “Hold.” KVUE’s average analyst price target is $24.50, indicating a potential upside of 14.5% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
